1.It can be used to detect whether abnormalities occur in the IGH gene and for minimal residual disease monitoring.
2.Breakage of the IGH gene can serve as a marker of malignant clones in myeloma cells. It is not influenced by clinical staging or immunophenotype, making it a reliable basis for diagnosing multiple myeloma.